Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-25T05:35:48.387Z Has data issue: false hasContentIssue false
  • English
  • Français

An Economic Evaluation of the Introduction of Vaccination Against Hepatitis a in a Peacekeeping Operation: The Case of the United Nations Protection Force in Yugoslavia

Published online by Cambridge University Press:  10 March 2009

Tom Jefferson ,
Vittorio Demicheli  and
David Wright
Tom Jefferson
Affiliation:
Medical Directorate, British Army of the Rhine
Vittorio Demicheli
Affiliation:
University of Pavia
David Wright
Affiliation:
Royal Army Medical College, London
Get access Rights & Permissions [Opens in a new window]

Abstract

The costs and benefits of vaccinating troops on United Nations tours in Yugoslavia against hepatitis A were compared. The marginal cost of one case of hepatitis A avoided by vaccination was calculated and compared with the marginal cost of achieving the same outcome by passive immunization. The cost-benefit ratio (medium estimate) for troops at low risk of contracting hepatitis A was 0.01 and for those at high risk was 0.03.

Vaccinating troops against hepatitis A for a single deployment appears to be an inefficient procedure, especially in troops at low risk. However, in professional troops from countries of low hepatitis A endemicity who are likely to be involved in several operational deployments, vaccination becomes more efficient the more times the same troops are deployed.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 3 , Summer 1994 , pp. 490 - 497
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Demicheli, V., & Jefferson, T. O.Cost-benefit analysis of mass vaccination against Hepatitis B in Italy. Journal of Public Health Medicine, 1992, 14, 367–75.CrossRefGoogle ScholarPubMed
2.Demicheli, V., & Jefferson, T. O.Le consequenze economiche della Salmonellosi. Rivista Italiana di antibioticoterapia per la Pratica, 991, 2, 73–81.Google Scholar
3.Jefferson, T. O.Public health aspects of the war in Yugoslavia. Public Health, 1993, 107, 75–8.CrossRefGoogle ScholarPubMed
4.Johnson, A. O., Akinbami, E. D., Ekambi, N. et al. Patterns of childhood hepatitis in the Nigerian African. IARC Scientific Publications, 1984, 63, 131–41.Google Scholar
5.Hoke, C. H., Binn, I. N., et al. Hepatitis A in the US army: Epidemiology and vaccine development. Vaccine, 1992, suppl. 1:S75–79.CrossRefGoogle Scholar
6.Piazza, M.Epatite virale acuta e cronica. Milano: Ghedini, 1990, 53.Google Scholar
7.Tilzey, A. J., & Banatvala, J. E.Hepatitis A. BMJ, 1991, 302, 1552–53.CrossRefGoogle ScholarPubMed
8.Tilzey, A. J., Palmer, S. J., Barrow, S., et al. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ, 1992, 304, 1272–6.CrossRefGoogle ScholarPubMed
9.Tormans, G., Van Damme, P., & Van Doorslaer, E. Cost-effectiveness analysis of hepatitis A prevention in travellers. Vaccine, 1992, suppl 1, S88–92.CrossRefGoogle Scholar
10.Tormans, G., Van Damme, P., & Van Doorslaer, E.Economic evaluation of Hepatitis A prevention. ESOC Publication number 23. Antwerp: University of Antwerp, 1992.Google ScholarPubMed
11.Weiland, O., Berg, J. V. R., Back, E., & Lundbergh, P.Immunoglobulin prophylaxis against Hepatitis A among Swedish UN soldiers in an endemic region. Infection, 1979, 7, 223–25.CrossRefGoogle Scholar
12.Werzberger, A., Mensch, B., Kuter, B., et al. A controlled trial of a formalin-inactivated Hepatitis A vaccine in healthy children. New England Journal of Medicine, 1992, 327, 453–57.CrossRefGoogle ScholarPubMed